{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"11.0","value":"10.0"},{"groupId":"OG001","lowerLimit":"10.0","upperLimit":"11.0","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\\*10\\^9/L for 3 consecutive days or ≥ 1.0\\*10\\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of plerixafor for a maximum of 4 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"G-CSF Plus Plerixafor"},{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of placebo for a maximum of 4 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"G-CSF Plus Placebo"}],"paramType":"MEDIAN","populationDescription":"Participants who received a stem cell transplant.","reportingStatus":"POSTED","timeFrame":"Up to Month 13","title":"Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment","type":"SECONDARY","unitOfMeasure":"Days"}